These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32090985)

  • 1. Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood.
    Naito Y; Osa A; Masuhiro K; Hirai T; Koyama S; Kumanogoh A
    J Vis Exp; 2020 Feb; (156):. PubMed ID: 32090985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab.
    Pluim D; Ros W; Miedema IHC; Beijnen JH; Schellens JHM
    Cytometry A; 2019 Oct; 95(10):1053-1065. PubMed ID: 31407460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.
    Zelba H; Bochem J; Pawelec G; Garbe C; Wistuba-Hamprecht K; Weide B
    Cancer Immunol Immunother; 2018 Dec; 67(12):1845-1851. PubMed ID: 30218171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
    Osa A; Uenami T; Koyama S; Fujimoto K; Okuzaki D; Takimoto T; Hirata H; Yano Y; Yokota S; Kinehara Y; Naito Y; Otsuka T; Kanazu M; Kuroyama M; Hamaguchi M; Koba T; Futami Y; Ishijima M; Suga Y; Akazawa Y; Machiyama H; Iwahori K; Takamatsu H; Nagatomo I; Takeda Y; Kida H; Akbay EA; Hammerman PS; Wong KK; Dranoff G; Mori M; Kijima T; Kumanogoh A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    England CG; Jiang D; Ehlerding EB; Rekoske BT; Ellison PA; Hernandez R; Barnhart TE; McNeel DG; Huang P; Cai W
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):110-120. PubMed ID: 28821924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.
    Fessas P; Lee H; Ikemizu S; Janowitz T
    Semin Oncol; 2017 Apr; 44(2):136-140. PubMed ID: 28923212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.
    Ogasawara R; Hashimoto D; Sugita J; Yamawaki F; Naka T; Mitsuhashi T; Takahashi S; Miyashita N; Okada K; Onozawa M; Matsuno Y; Teshima T
    Int J Hematol; 2020 Mar; 111(3):475-479. PubMed ID: 31538325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 expression by canine T cells and functional effects of PD-1 blockade.
    Coy J; Caldwell A; Chow L; Guth A; Dow S
    Vet Comp Oncol; 2017 Dec; 15(4):1487-1502. PubMed ID: 28120417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.
    Medina PJ; Adams VR
    Pharmacotherapy; 2016 Mar; 36(3):317-34. PubMed ID: 26822752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
    Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J
    Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 checkpoint inhibition: Toxicities and management.
    Hahn AW; Gill DM; Agarwal N; Maughan BL
    Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
    Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M
    Commun Biol; 2019; 2():392. PubMed ID: 31667366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry.
    Tavares ABMLA; Lima Neto JX; Fulco UL; Albuquerque EL
    Sci Rep; 2018 Jan; 8(1):1840. PubMed ID: 29382901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid, sensitive and cost-effective determination of immune checkpoint inhibitor activity using a magnetic bead-based binding assay.
    Meng Q; Fu Y; Li S; Yan Y; Duan D; Anthony DD; Zhu Y; Wu X; Qian F; Wu C
    J Immunol Methods; 2021 Nov; 498():113134. PubMed ID: 34464606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.